Antibody Synthesis

 

Antibody Synthesis service provides synthesis and cloning of your antibody heavy/light chain sequences into any custom vector in as few as 6 days. This is the fastest turnaround time on the market. Our high-quality results are paired with FREE recombinant antibody expression optimization and FREE cloning vector storage for up to 2 years.

GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences offers a customer-friendly antibody synthesis service with Ph.D.-level technical support to alleviate common synthesis obstacles and streamline your antibody discovery research.

 


Accelerating Antibody-Drug Conjugate (ADC)
Discovery with High-Throughput rAb Screening

Thursday, September 19, 2024 | 11:00AM EDT

 

 

What is the process of Antibody Synthesis?

Antibody synthesis is the production of antibodies – proteins created by the immune system of a host — in response to an antigen, a foreign body that enters the host. The production of an antibody involves several steps:

  • Preparation of the immunogen
  • Immunization
  • Creation of a hybridoma
  • Collection
  • Screening
  • Isotyping
  • Purification of the antibody
  • Antibody labeling for direct use

Antibody Synthesis Features & Benefits

Rapid Turnaround Time – Starting at just 6 days to meet your project deadlines
Quality Control – Stringent quality control with guaranteed 100% sequence accuracy
Vector Storage – FREE cloning vector storage for up to 2 years
Codon Optimization – Optimize recombinant antibody expression using our FREE codon optimization tool
Large-Scale Plasmid Prep – Multiple plasmid DNA preparation options from ug to mg
Ph.D.-Level Customer Support – Our dedicated Project Management team provides consultation and support for your project, from start to finish

FASTEST ANTIBODY DNA SYNTHESIS ON THE MARKET

Synthetic Gene Length Turnaround Time (TAT)
<500 bp
6-8 Business Days
501-750 bp
751-1500 bp 8-10 Business Days
Custom cloning No Additional TAT



OMICS TECHNOLOGY SPOTLIGHT WEBINAR

An Innovative Antibody Discovery Workflow
Leveraging Machine Learning to Prioritize Leads

Thursday, June 27, 2024 | 11:00AM EDT



 

Synthesize all types of DNA Sequences for Antibody Research

Advancements in recombinant monoclonal antibody (rAb) technology have led to the development of a variety of engineered antibody molecules for research, diagnosis, and therapy. With over 10 years of expertise in gene synthesis and cloning, GENEWIZ has supported numerous antibody discovery and development projects, including researchers developing broadly anti-virus monoclonal antibodies [1], bispecific recombinant antibodies [2], anticancer Fc-engineered human monoclonal antibody [3, 4], and much more.


Figure 1. Synthetic DNA in antibody development

Recombinant antibodies can be developed using de novo synthesis of recombinant VDJ light chain and heavy chain sequences. Synthetic DNA can be also used in humanized or other recombinant antibodies such as single-chain variable fragment (scFv), single domain antibody (sdAb), fragment antigen binding mAb (Fab), trifunctional antibody, etc.

WHAT OUR CUSTOMERS ARE SAYING

“I have always had great customer service from GENEWIZ, received great products with a good price. It allows me to do other things in the lab instead of spending time cloning, etc.”
- Researcher from Cincinnati Children's Hospital Medical Center


“Good quality, customer support, and expediated delivery to help me to meet the deadline.”
- Principal Investigator from a top pharmaceutical company

Application Note | Accelerating Recombinant Antibody Production

Recombinant antibody production is a cornerstone of modern biotechnology and research, but it faces the significant challenge of achieving high yields. In this application note, discover how to enhance expression efficiency while reducing production times with an optimized vector backbone workflow.

RELATED PUBLICATIONS

[1]Xiao H, Guo T, Yang M, et al. Light chain modulates heavy chain conformation to change protection profile of monoclonal antibodies against influenza A viruses. Cell Discov. 2019;5:21. Published 2019 Apr 16. doi:10.1038/s41421-019-0086-x

[2]Ahmed M, Lopez-Albaitero A, Pankov D, et al. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 2018;3(4):e97805. Published 2018 Feb 22. doi:10.1172/jci.insight.97805

[3] Qi X, Li F, Wu Y, et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019;10(1):2141. Published 2019 May 20. doi:10.1038/s41467-019-10088-1

[4]Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Cancer Cell. 2016;29(6):820–831. doi:10.1016/j.ccell.2016.05.001

STREAMLINE YOUR PATH TO DISCOVERY

Gene-to-Discovery Solutions

AAV Packaging, Custom mRNA Synthesis, Lentivirus Packaging, Recombinant Antibody Production


HOW TO ORDER

*Samples must arrive at the GENEWIZ New Jersey laboratory before 10:00 am EST to qualify for Same Day service. Note that direct-sequencing templates are not available for our Same Day service.


Email: gs@azenta.com | Phone: +49 (0)341 520 122-41